ArticleWorld journal of psychiatry2025
Erythrocyte membrane nervonic acid in drug-naive first-episode psychosis and chronic medicated schizophrenia: Implication for impaired myelination and prognosis.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNervonic acid (NA, C24: 1, w9) is a monounsaturated fatty acid that plays a crucial role in myelination and motor function. It also regulates cognitive and metabolic functions, suggesting that impaired NA metabolism may contribute to the pathophysiology of schizophrenia. Although several studies have measured erythrocyte membrane NA in first-episode psychosis (FEP), findings are conflicting, and the fate of NA in patients with chronic schizophrenia (CSZ) or under long-term antipsychotic treatment schedules remains unknown.
aimTo measure erythrocyte membrane NA and determine its association with psychopathology and metabolic parameters in drug-naive patients with FEP and antipsychotic-treated patients with CSZ.
methodsIn this study, twenty-one drug-naive patients with FEP, twenty patients with CSZ treated with atypical antipsychotics, and fourteen healthy male subjects were analyzed. Erythrocyte membrane NA was measured using ultrathin capillary gas chromatography, plasma leptin was measured using enzyme-linked immunosorbent assay, and body mass index (BMI) was calculated by using the formula: Weight (kg)/height (m²). Psychiatric symptoms were evaluated using the brief psychiatry rating scale and the positive and negative syndrome scale (PANSS). Pearson correlation coefficient (
resultsIn patients with FEP, erythrocyte NA was non-significantly increased (about 12%) and negatively correlated with negative symptoms (PANSS-negative symptom scores,
conclusionErythrocyte membrane NA level could be used for predicting the development of metabolic abnormalities, treatment resistance, and prognosis in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.